Malignt neuroleptikasyndrom--sällsynt diagnos med hög dödlighet.
(2009) In Läkartidningen 106(18-19). p.1273-1276- Abstract
- Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal condition characterised by increased body temperature and muscle rigidity in a patient receiving antipsychotic treatment. Diagnosis also requires the presence of two symptoms of autonomic dysfunction and/or leukocytosis and increased creatin kinase. All neuroleptics, including atypical agents, can cause the condition, which is thought to arise from dopamine receptor blockade in the striatum and hypothalamus. Treatment includes withdrawal of the antipsychotic agent, intensive care, and pharmacological therapy with bensodiazepines, bromocriptine and dantrolene, as well as ECT in refractory cases. Significant differential diagnoses are encephalitis, serotonin syndrome, and... (More)
- Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal condition characterised by increased body temperature and muscle rigidity in a patient receiving antipsychotic treatment. Diagnosis also requires the presence of two symptoms of autonomic dysfunction and/or leukocytosis and increased creatin kinase. All neuroleptics, including atypical agents, can cause the condition, which is thought to arise from dopamine receptor blockade in the striatum and hypothalamus. Treatment includes withdrawal of the antipsychotic agent, intensive care, and pharmacological therapy with bensodiazepines, bromocriptine and dantrolene, as well as ECT in refractory cases. Significant differential diagnoses are encephalitis, serotonin syndrome, and lethal catatonia. It is thought that NMS, serotonin syndrome, and lethal catatonia constitute a spectrum of a neurobiological condition characterised by dopaminergic hypofunction as well as serotoninergic hyperfunction. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1434132
- author
- Petersén, Åsa LU and Lundberg, Louise
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Catatonia: diagnosis, Neuroleptic Malignant Syndrome: diagnosis, Serotonin Syndrome: diagnosis, Neuroleptic Malignant Syndrome: mortality, Neuroleptic Malignant Syndrome: complications
- in
- Läkartidningen
- volume
- 106
- issue
- 18-19
- pages
- 1273 - 1276
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:19537499
- scopus:67549093399
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- yes
- id
- 44bfb39a-5c5b-4573-94df-5f5882398489 (old id 1434132)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19537499?dopt=Abstract
- http://ltarkiv.lakartidningen.se/artNo36525
- date added to LUP
- 2016-04-04 09:27:58
- date last changed
- 2022-01-29 18:00:12
@article{44bfb39a-5c5b-4573-94df-5f5882398489,
abstract = {{Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal condition characterised by increased body temperature and muscle rigidity in a patient receiving antipsychotic treatment. Diagnosis also requires the presence of two symptoms of autonomic dysfunction and/or leukocytosis and increased creatin kinase. All neuroleptics, including atypical agents, can cause the condition, which is thought to arise from dopamine receptor blockade in the striatum and hypothalamus. Treatment includes withdrawal of the antipsychotic agent, intensive care, and pharmacological therapy with bensodiazepines, bromocriptine and dantrolene, as well as ECT in refractory cases. Significant differential diagnoses are encephalitis, serotonin syndrome, and lethal catatonia. It is thought that NMS, serotonin syndrome, and lethal catatonia constitute a spectrum of a neurobiological condition characterised by dopaminergic hypofunction as well as serotoninergic hyperfunction.}},
author = {{Petersén, Åsa and Lundberg, Louise}},
issn = {{0023-7205}},
keywords = {{Catatonia: diagnosis; Neuroleptic Malignant Syndrome: diagnosis; Serotonin Syndrome: diagnosis; Neuroleptic Malignant Syndrome: mortality; Neuroleptic Malignant Syndrome: complications}},
language = {{swe}},
number = {{18-19}},
pages = {{1273--1276}},
publisher = {{Swedish Medical Association}},
series = {{Läkartidningen}},
title = {{Malignt neuroleptikasyndrom--sällsynt diagnos med hög dödlighet.}},
url = {{http://www.ncbi.nlm.nih.gov/pubmed/19537499?dopt=Abstract}},
volume = {{106}},
year = {{2009}},
}